GLPwatch
GLP-1 agonists to slow down Parkinson's progression? The quest continues.
Med · 2025
Last updated 2026-05-28A large phase 3 clinical trial called EXENATIDE-PD3 tested whether the GLP-1 drug exenatide could slow Parkinson’s disease progression. The study found no difference between exenatide and a placebo in improving symptoms or other measured outcomes. The results suggest exenatide does not provide neuroprotective benefits for Parkinson’s disease.
AI summary of the abstract below.
| Journal | Med, 2025 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 2.15 |
| Molecules | — |
| Conditions studied | Parkinsons |
Abstract
A much-anticipated phase 3 clinical trial (EXENATIDE-PD3) tested whether exenatide, a GLP-1 receptor agonist used to treat type 2 diabetes, might be neuroprotective in persons with Parkinson's disease. There was no difference between exenatide and matched placebo for the primary outcome or any secondary or exploratory outcomes. We discuss the implications for future attempts to modify the course of Parkinson's disease.
Verbatim abstract via PubMed 40220748 ↗